Per the collaboration, preclinical research will be carried out by G-CURE at the University Medical Center Groningen (UMCG) experimental cardiology laboratory. QPS will work from its preclinical ADME laboratories in Newark, Delaware and/or its fully GLP compliant toxicology laboratories in Taipei, Taiwan.
“By joining forces we both expect to be able to extend our sponsor networks,” Ben Chien, CEO of QPS Holdings, LLC told Outsourcing-Pharma.com. “Second, we are unique in our set-up in which we can do both healthy volunteer and cardiac patient studies in one setting.”
According to the company, the three preclinical testing facilities will provide a “broad technical platform” to speed early development.
“Together, we hope to be at the forefront of the development of innovative cardiac drugs that will hopefully ultimately improve the lives of patients suffering from cardiac diseases,” said Chien.
“The next step will be to explore each other’s network and actively look for early cardiac drug development programs that we can execute together.”